Restoration of miR-26b Expression Partially Reverses the Cisplatin Resistance of NSCLC by Targeting Tafazzin

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s212649
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

ABT737 Reverses Cisplatin Resistance by Targeting Glucose Metabolism of Human Ovarian Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2018English

miR‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2

Oncology Reports
MedicineCancer ResearchOncology
2018English

miR-625 Reverses Multidrug Resistance in Gastric Cancer Cells by Directly Targeting ALDH1A1

Cancer Management and Research
Oncology
2019English

Exosomal Transfer of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance in NSCLC Through Activating Autophagy

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2019English

miR-186 Reverses Cisplatin Resistance and Inhibits The�formation of the Glioblastoma-Initiating Cell�phenotype by Degrading Yin Yang 1 in Glioblastoma

International Journal of Molecular Medicine
MedicineGenetics
2018English

MiR-519d Impedes Cisplatin-Resistance in Breast Cancer Stem Cells by Down-Regulating the Expression of McL-1

Oncotarget
Oncology
2017English

Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma

Cells
2018English

miRNA-378 Reverses Chemoresistance to Cisplatin in Lung Adenocarcinoma Cells by Targeting Secreted Clusterin

Scientific Reports
Multidisciplinary
2016English

Epigenetic Silencing of miR-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3

Oncogene
Cancer ResearchGeneticsMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy